Side-by-side comparison of AI visibility scores, market position, and capabilities
FogPharma develops cell-penetrating mini-proteins (CPMPs) to target intracellular cancer drivers like beta-catenin and FOXM1 that are undruggable by antibodies; raised $174M including a $100M Series C in 2023;
FogPharma is a clinical-stage biopharmaceutical company founded in 2015 by Gregory Verdine and headquartered in Cambridge, Massachusetts, developing a novel class of cancer therapeutics based on cell-penetrating mini-proteins (CPMPs). Traditional cancer drugs fall into two broad categories: small molecules that can penetrate cells but struggle to bind complex protein surfaces, and antibodies that bind complex surfaces with high specificity but cannot enter cells. FogPharma's CPMPs are designed to do both — penetrate cell membranes and engage large, complex intracellular protein targets that cause cancer but have historically been considered undruggable.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.